Development of cytokine gene therapy with high therapeutic index by systemic regulation of transgene expression and biological response.
| Project/Area Number |
15H04638
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高橋 有己 京都大学, 薬学研究科, 准教授 (00547870)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2017: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2016: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Keywords | 遺伝子治療 / サイトカイン / プラスミドDNA / ドラッグデリバリー / インターフェロン / 抗原特異的免疫応答 |
|---|
| Outline of Final Research Achievements |
Interferon-β(IFNβ) is a cytokine with pleiotropic and potent bioactivity. In this study, effective IFNβ gene therapy was developed. First, a plasmid vector named as pMX- IFNβ, which is driven by Mx promoter, was developed to achieve sustained IFNβ transgene expression. Sustained IFNβ expression from pMX- IFNβ was effective in treating cancer and multiple sclerosis (MS) in model mice. Moreover, by designing a fusion protein of galectin-9 (gal9) and IFNβ named as IFNβ-gal9, it was succeeded in improving therapeutic effect of IFNβ on MS and reducing adverse effect of IFNβ. In conclusion, IFN gene therapy with high therapeutic index was successfully developed.
|
Report
(4 results)
Research Products
(8 results)
